Granulocyte Colony-Stimulating Factor (Filgrastim) Treatment Primed for Increased ex Vivo Inducible Prostanoid Release

Sonja von Aulock, Eva-Maria Boneberg, Isabel Diterich, and Thomas Hartung
Biochemical Pharmacology, University of Konstanz, Konstanz, Germany
Received August 5, 2003; accepted November 7, 2003

ABSTRACT
We investigated whether anti-inflammatory effects of treatment with granulocyte colony-stimulating factor (G-CSF, filgrastim) are mediated via prostaglandin E₂ (PGE₂) induction. In a double-blind crossover study, 10 healthy volunteers received 300 μg of filgrastim or saline 1 week apart. This was repeated after oral administration of 50 mg of flurbiprofen 1 h before injection. The increase in neutrophilic granulocytes initiated by G-CSF was augmented significantly by flurbiprofen. Lipopolysaccharide-induced PGE₂ and thromboxane (TxB₂) release were increased 8 h after G-CSF treatment. This increase was abrogated by flurbiprofen. However, flurbiprofen did not affect G-CSF-mediated decrease in tumor necrosis factor-α or interferon-γ release. Of the volunteers treated with G-CSF, eight reported side effects (headache and bone pain) against none in the saline group. When flurbiprofen was given before injection, one volunteer each reported side effects in the G-CSF and in the saline group. These data show that G-CSF primes for increased PGE₂ and TxB₂ release. Cyclooxygenase inhibition counteracts neither the hematopoietic nor the anti-inflammatory activity of G-CSF but reduces side effects.

The granulocyte colony-stimulating factor (G-CSF) has been available in recombinant form as filgrastim (Neupogen) or lenograstim (Granocyte) for over a decade. It is used in the clinic to restore neutrophil counts and prime neutrophil functions to protect vulnerable patients from infection. G-CSF is approved for treatment of patients undergoing chemotherapy or also patients with acute neutropenia due to HIV (human immunodeficiency virus) infection.

Apart from increasing the production of neutrophilic granulocytes, continuous G-CSF administration also increases monocyte and lymphocyte production (Hartung et al., 1999; von Aulock et al., 2000). Also, G-CSF has anti-inflammatory effects on monocytes, increasing the release of cytokine antagonists, i.e., IL-1 receptor antagonist and the soluble TNF receptors; reducing the proinflammatory cytokine response, i.e., TNFα, IL-1β, IL-12, and consequently the lymphokine IFNγ; and increasing the release of IL-6 and IL-8, in response to immune stimuli ex vivo (Hartung et al., 1995, 1999; Boneberg et al., 2000). These effects may be beneficial for immunoreconstitution of patients with HIV after initiation of highly active antiretroviral therapy (von Aulock and Hartung, 2002). In vitro, G-CSF decreases LPS-stimulated transcription of TNFα, but IL-1β release is modulated on the level of pro-IL-1β processing (Boneberg et al., 2000; Boneberg and Hartung, 2002).

The side effects most commonly reported under G-CSF treatment are headache and mild bone pain, symptoms resembling the onset of a cold. However, the mechanism responsible for these side effects has not been investigated. Because prostaglandin (PG)E₂ is considered the main mediator of pain, but also reduces the production of TNFα on the transcriptional level (Spatafora et al., 1991), we considered it a likely candidate to mediate the anti-inflammatory effects as well as the side effects of G-CSF.

Measurement of eicosanoid release by blood in response to stimulation has mainly been used to establish selectivity of NSAIDs (Glaser et al., 1995; Brideau et al., 1996; Riendeau et al., 2001; Blain et al., 2002). Eicosanoids regulate vasomotor and bronchotonus, induce pain and fever, and have immunosuppressive or chemotactic properties. Arachidonic acid released from the cells’ membrane in response to stimulation is converted to PGH₂ by constitutive cyclooxygenase-1 and inducible cyclooxygenase-2 (COX, prostaglandin-endoperoxide synthase). PGH₂ is then further metabolized by other enzymes to prostaglandins, prostacyclin, and thromboxanes. We have standardized a method to measure eicosanoid release in supernatants from in vitro-stimulated whole blood.

ABBREVIATIONS: G-CSF, granulocyte colony-stimulating factor; IL, interleukin; TNFα, tumor necrosis factor-α; IFNγ, interferon-γ; LPS, lipopolysaccharide; PG, prostaglandin; NSAID, nonsteroidal anti-inflammatory drug; COX, cyclooxygenase; TxB₂, thromboxane B₂; LTB₄, leukotriene B₄; U46.619, 9,11-dideoxy-11α,9α-epoxy methanoprostaglandin F₂α.
incubations (von Aulock et al., 2003), which can also be used in the clinic to investigate the role of eicosanoid release in the course of diseases and to clarify correlations between cytokines and eicosanoids measured in the same samples. This report also describes the induction of eicosanoids by numerous other immune stimuli. For the present study, the well established stimulus LPS at a high concentration was chosen as a standard to assess eicosanoid release capacity.

Here, we investigate the effects of G-CSF treatment on eicosanoid release capacity and whether these eicosanoids play a role in the modulation of cytokine release by G-CSF by combining COX inhibition and G-CSF treatment.

**Materials and Methods**

**Volunteer Population.** The study protocol was reviewed and approved by the institutional review board of the University of Konstanz. All subjects gave written informed consent before study entry. Ten healthy Caucasian male volunteers, aged 22 to 32 years (28 ± 1 years) and weighing 77 ± 2 kg, were enrolled. The volunteers were free from signs or symptoms of acute infectious disease and had no history of clinically significant disease and took no medication for 4 weeks before the study.

**Study Design.** The protocol was double-blind and placebo-controlled for G-CSF treatment but unblinded for flurbiprofen treatment. Ten healthy male volunteers were randomized to two treatment groups, which were crossed over for G-CSF treatment. There was 1-week washout in between each of the four treatments. Clinical grade isoosmic saline or 300 µg of clinical grade, pyrogen-free filgrastim (Neupogen; Amgen, Munich, Germany) was administered s.c. at 9:00 AM in week 1 and crossed over in week 2. This was repeated in weeks 3 and 4 and additionally every volunteer was given one 50-ng tablet of flurbiprofen (Frob; BASF Pharma, Abbott, Switzerland) at 8:00 AM, i.e., 1 h before the injection (Table 1).

Blood samples were collected immediately before treatment at 8:00 AM, 9:00 AM, and 5:00 PM on every day of treatment and at 9:00 AM on the following day. The volunteers had the right to withdraw from the study drug and study at any time for any reason. Volunteers would have been removed from the study in case of significant protocol violation, unacceptable side effects, or unrelated medical illness. No one withdrew from the study or was removed.

**Differential Blood Counts.** Differential blood counts were routinely performed on the blood of all volunteers to rule out acute infections and to control for changes in leukocyte subpopulations with a Pentra60 (ARBX Diagnostics, Montpellier, France).

**Whole Blood Incubations.** Stimuli, i.e., LPS from Salmonella abortus equi or staphylococcal enterotoxin B (Sigma Chemie, Deisenhofen, Germany) or solvent, were added to 1600 µl of RPMI 1640 medium; BioWhittaker, Verviers, Belgium) supplemented with 100 IU/ml penicillin, 100 µg/ml streptomycin, and 2.5 IU/ml heparin (Liquemin; F. Hoffmann LaRoche, Grenzach-Whylen, Germany) and 400 µl of heparinized whole blood in 2-ml polypropylene tubes (Frohren; BASF Pharma, Abbott, Switzerland) at 8:00 AM, i.e., 1 h before the injection (Table 1).

TABLE 1

<table>
<thead>
<tr>
<th>Group</th>
<th>Week 1</th>
<th>Week 2</th>
<th>Week 3</th>
<th>Week 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 (n = 5)</td>
<td>Placebo(^a)</td>
<td>Filgrastim</td>
<td>Flurbiprofen(^c)</td>
<td>Filgrastim</td>
</tr>
<tr>
<td>2 (n = 5)</td>
<td>Filgrastim(^b)</td>
<td>Placebo</td>
<td>Placebo</td>
<td>Placebo</td>
</tr>
</tbody>
</table>

\(^a\) Isoosmic saline.
\(^b\) 300 µg of filgrastim s.c.
\(^c\) 50 mg of flurbiprofen p.o.
before and up to 24 h after treatment with 480 μg of G-CSF (n = 6) or placebo (n = 4) in samples from a study reported previously (Boneberg et al., 2000). Serum PGE₂ did not differ significantly between the placebo or G-CSF treatment groups either before treatment or 2, 4, 8, or 24 h after injection (Fig. 2; mean values in serum without treatment were 227 ± 17 pg/ml). Therefore, both in vitro and in vivo results concur, indicating that G-CSF treatment does not induce physiologically relevant endogenous systemic PGE₂ release.

However, when 10 volunteers were injected with 300 μg of G-CSF, ex vivo LPS-inducible PGE₂ and TxB₂ levels in whole blood incubations were increased about 3- and 2-fold, respectively, above levels induced in blood from placebo-treated volunteers 8 h after treatment. Twenty-four hours after treatment, inducible prostanoid levels were again similar in both groups (Fig. 3a). In the same samples, LPS-inducible TNFα release calculated per monocyte was halved in blood from G-CSF-treated volunteers, whereas IFNγ release was reduced to one-third of placebo values (Fig. 3b). Incidentally, although LPS-inducible TNFα release did not vary significantly over the course of a day, IFNγ release was consistently greater in blood drawn in the afternoon compared with blood drawn in the morning.

In the second half of the treatment study, one 50-mg tablet of flurbiprofen was given 1 h before G-CSF or placebo injection. Blood samples were taken immediately before administration of flurbiprofen and immediately before administration of G-CSF or placebo 1 h later and 8 h after injection of G-CSF or placebo, i.e., 9 h after administration of flurbiprofen. Figure 4 confirms that flurbiprofen is very effective in reducing LPS-induced PGE₂ and TxB₂ release within 1 h of ingestion. The observation that the values before any treatment (t = −1 h) in the group receiving flurbiprofen and placebo were higher than in the other groups is a result of day-to-day variation. This stresses further the strength of the effect, i.e., the difference is even greater when the prostanoid values induced before treatment (t = 1 h) in the group receiving flurbiprofen and placebo were higher than in the other groups is a result of day-to-day variation. This stresses further the strength of the effect, i.e., the difference is even greater when the prostanoid values induced before treatment (t = −1 h) are compared with those 1 h after ingestion (t = 0 h) in that group. This effect was still in place 9 h after ingestion of the tablet, i.e., 8 h after placebo or G-CSF injection. Twenty-four hours after ingestion of flurbiprofen, LPS-inducible PGE₂ levels were still decreased compared with starting values, although TxB₂ levels had returned to pretreatment values.

Although prostanoid release was attenuated when flurbiprofen was given before G-CSF injection, TNFα release per monocyte and IFNγ release per lymphocyte remained significantly below placebo values at levels equal to values attained under G-CSF treatment without prior flurbiprofen treatment (Fig. 5) even though initial LPS-inducible IFNγ release at t = −1 h and t = 0 h was significantly greater in

Fig. 1. G-CSF does not modulate LPS-induced PGE₂ release in vitro. Whole blood (20%) from 10 donors was stimulated with 10 μg/ml LPS (hatched bars) or 10 μg/ml LPS plus 100 ng/ml G-CSF (black bars) overnight. PGE₂ and TNFα were measured in the supernatant. Data are means ± S.E.M.; n.s., not significant; ***, p < 0.001.

Fig. 2. G-CSF administration does not alter the levels of serum PGE₂. Serum levels of PGE₂ were measured in healthy volunteers treated with 480 μg of G-CSF (filgrastim) (n = 6) or placebo (n = 4) at the time points indicated. The study design was reported earlier (Boneberg et al., 2000). Data are normalized to placebo (set to 100% for each time point) ± S.E.M. There were no significant differences between the two groups at any time point.

Fig. 3. G-CSF treatment modulates LPS-induced prostanoïd and cytokine release. Prostanoid (TxB₂ and PGE₂) and cytokine (TNFα and IFNγ calculated per 10⁶ monocytes or lymphocytes, respectively) release in response to 10 μg/ml LPS from S. abortus equi. Times are given relative to injection of 300 μg of G-CSF (filgrastim) or placebo. Initial values are set to 100%, values are means ± S.E.M.; **, p < 0.01; ***, p < 0.001.
the group receiving flurbiprofen and G-CSF compared with the other groups.

Interestingly, the combination of flurbiprofen with G-CSF treatment did not counteract G-CSF-induced leukocytosis, but instead actually added significantly to the effect. The differential blood cell counts revealed that flurbiprofen had further increased the recruitment of neutrophilic granulocytes, indicating that the prostanoids play a role in controlling neutrophil production negatively (Fig. 6). A carryover effect from the first G-CSF treatment on the leukocyte counts was excluded by the differential blood cell count. However, it cannot be ruled out that the greater efficacy of the second G-CSF injection 2 weeks after the first treatment could be due to a larger marrow pool of neutrophils. On the other hand, we have no indications for such effects from a previous study in which volunteers received G-CSF treatment on a weekly basis (von Aulock et al., 2000).

Volunteers were asked about side effects on the day after every treatment. Eight of 10 volunteers reported headache or bone pain after G-CSF treatment against zero complaints from the placebo-treated volunteers. However, when volunteers received flurbiprofen before G-CSF injection, one volunteer reported side effects in both the placebo and the G-CSF-treated group. It seems that the side effects commonly associated with G-CSF treatment are mediated by eicosanoids and can be prevented effectively by cyclooxygenase inhibition without interfering negatively with neutrophil recruitment or with the anti-inflammatory effects of G-CSF treatment.

**Discussion**

The results presented in this article demonstrate that there is a significant discrepancy between the effects of G-CSF in vitro in comparison to ex vivo with regard to the modulation of prostanoid release. Incubation of whole blood with G-CSF in vitro decreases LPS-stimulated release of TNFα or IFNγ as can also be seen in blood from G-CSF-treated volunteers even 24 h after treatment. However, whole blood preincubated with G-CSF in vitro was not able to bring about the priming for eicosanoid release that could be observed in ex vivo-stimulated blood from G-CSF-treated volunteers. Apparently, the cells recruited by G-CSF from the bone marrow differ in their characteristics compared with the more mature population found in the blood of un-
treated donors. It seems unlikely that the increased prostanoid levels induced in blood from G-CSF-treated volunteers on stimulation merely reflect increased populations of the producing cells, because the priming can only be observed 8 h after G-CSF treatment and baseline values are achieved 24 h after treatment, whereas the cell counts still significantly increased during this time period. This observation poignantly illustrates that not all effects of G-CSF can be modeled in vitro. Although the ex vivo effects of G-CSF on TNF formation could also be modeled in vitro, this did not translate to its effects on eicosanoids. This suggests that G-CSF treatment recruits a different population of peripheral leukocytes.

The lack of effect of G-CSF on the serum levels of PGE$_2$ suggests that the nature of the effect of G-CSF treatment is limited to priming for increased response to inflammatory stimuli, and not to direct activation of cells. Even at a higher dose than given in the main study, there was no effect on PGE$_2$ levels; in fact, the tendency toward lower PGE$_2$ levels compared with the placebo group and to the values before G-CSF treatment does not give rise to expectations that this would be different with even lower doses of G-CSF.

It is not clear which cells in the blood are the main producers of prostanoids. TxB$_2$ and PGE$_2$ can be released by both monocytes and neutrophils (Nichols et al., 1987; Doerfler et al., 1989; Nusing et al., 1990; Zheng et al., 1990; Juergens et al., 1992; Saareks et al., 1993; Patrignani et al., 1994; Aibiki and Cook, 1997), although this was not found for both populations by all investigators. Furthermore, platelets, which were also present in the whole blood incubations, express the highest amounts of thromboxane synthase (Nusing et al., 1990) and can release TxB$_2$, not only in response to coagulation, which was prevented here with heparin, but also in response to inflammatory stimulation (Saareks et al., 1993; Reale et al., 1996). In contrast, intracellular cytokine staining of LPS-stimulated whole blood showed that TNF is produced exclusively by monocytes (Boneberg and Hartung, 2002) in this experimental setup. Similarly, IFN$\gamma$ is clearly produced only by lymphocytes (Okamura et al., 1998; Boneberg et al., 2000), allowing a relation of the release of these cytokines to the producing cell numbers and accounting for the changes in differential blood cell counts due to the treatment.

PGE$_2$ was able to inhibit LPS-induced TNF as well as IFN$\gamma$ release in vitro, making it a candidate mediator of the anti-inflammatory effects of G-CSF in vivo. The strong increase in LPS-induced PGE$_2$ and TxB$_2$ induction under G-CSF treatment was already realized 8 h after treatment. However, effective inhibition of prostanoid production by additional administration of flurbiprofen did not restore LPS-induced proinflammatory cytokine release. The similarity in the effects of PGE$_2$ and G-CSF in reducing the release of TNF and IFN$\gamma$ prompted the hypothesis of an induction of PGE$_2$ by G-CSF. However, the anti-inflammatory effects of G-CSF were not attenuated by NSAID in vitro (Fig. 1) or ex vivo (Fig. 4). These results prove the hypothesis, that the anti-inflammatory effects of G-CSF require prostaglandin mediation, false. Instead, the reduction in the release of proinflammatory cytokines seems to be a direct effect of G-CSF on monocytes, which carry a functional G-CSF receptor (Boneberg et al., 2000).

Although flurbiprofen administration alone had no significant effects on the whole blood cell count, it significantly augmented the hematopoietic effects of G-CSF by recruiting additional neutrophils. This observation substantiates previous observations in rodent cells attributing a granulocyte colony-inhibitory activity to PGE$_2$ (Gentile and Pelus, 1988; Santangelo et al., 2000). A mechanism explaining this observation has not yet been put forward; a likely explanation is that the endogenously formed prostanooid regulates hematopoiesis negatively.

It also remains to be tested whether the combination of G-CSF with NSAIDs could further increase granulopoiesis in

![Fig. 6. Flurbiprofen treatment augments G-CSF-induced granulopoiesis. Whole blood cell count (a), differential neutrophilic granulocyte count (b), and monocyte count (c) in blood from volunteers. One 50-mg tablet of flurbiprofen was administered at t = -1 h and 300 µg of G-CSF (filgrastim) or placebo was injected at t = 0 h as indicated. All combinations of placebo versus G-CSF at 8 and 24 h were highly significantly different ($p < 0.001$). Values are means ± S.E.M.; *, $p < 0.05$; **, $p < 0.01$ relative to G-CSF without flurbiprofen.](https://jpet.aspetjournals.org/content/jpet/63/3/759/F6.large.jpg)
leukopenic patients. Pain management is commonly part of the treatment of these patients; therefore, this question might be answered by a retrospective analysis of clinical data.

It seems that PGE₂ may antagonize the granulopoietic effects of G-CSF to prevent excessive neutrophil recruitment. Although we found no difference in the PGE₂ serum levels of G-CSF-treated volunteers after G-CSF administration, the time points were possibly chosen too early and too late because the reported side effects usually occurred within 8 to 16 h of administration. However, serum samples from a former G-CSF treatment study with higher resolution also showed no elevation of serum PGE₂. On the other hand, PGE₂ release in vivo might not be systemic and might only work locally within the bone marrow.

However, the type of side effects reported, i.e., headache and bone pain, which are consistently reported under G-CSF treatment, do support the hypothesis that PGE₂ may be induced directly in vivo by high concentrations of G-CSF as a negative feedback. The effectiveness of prior flurbiprofen administration in preventing the side effects associated with G-CSF administration further supports this concept.

Together, these data show that G-CSF primes for increased PGE₂ and TxB₂ release ex vivo. Cyclooxygenase inhibition counteracts neither the hematopoietic nor the anti-inflammatory activity of G-CSF but prevents associated side effects.

Acknowledgments

We thank Stefan Fennrich, Corinna Hermann, Pascal Renner, Susanne Deininger, and Lars Hareng for prompt help.

References


Address correspondence to: Dr. Thomas Hartung, Biochemical Pharmacology, University of Konstanz, P.O. Box M655, 78457 Konstanz, Germany.

E-mail: thomas.hartung@uni-konstanz.de